Company intelligence / Profile preview

Fuzionaire Diagnostics

The Woodlands, Texas, United States

Ownership: Private
Development stage: Other

Overview

Preclinical oncology pipeline targeting GRPR-positive prostate cancer with 18F/68Ga PET diagnostics paired with 177Lu, 161Tb, 225Ac radioligand therapies; initial preclinical data presented in 2023.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

Nihon Medi-Physics Co., Ltd.McGill UniversityThe Neuro (Montreal Neurological Institute-Hospital)McMaster UniversityParaza PharmaAtomVie Global Radiopharma Inc.University Medical Center Mainz

Beyond the preview

Go deeper on Fuzionaire Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzionaire Diagnostics.

Explore the full profile